Treatment of IBD Moves Forward with Partnership Between Synlogic and AbbVie to Develop New Class of Medicines

Treatment of IBD Moves Forward with Partnership Between Synlogic and AbbVie to Develop New Class of Medicines
Synlogic recently announced the establishment of a global Research and Development collaboration with AbbVie to develop innovative medicines for the treatment of inflammatory bowel disease (IBD), taking advantage of Synlogic’s proprietary approach for a new class of synthetic biotic medicines powering the microbiome. As a privately-held biopharma based in Cambridge, Massachusetts, Synlogic is advancing the development

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. Sandra Mickelson says:

    This will certainly be wonderful. I do believe that it is the microbiome of our guts that is the major factor in the cause of IBD. It is unfortunate that the regulatory process is so slow. It takes the FDA far too long to process the trial results and take action. We will likely not see these new drugs approved and available for 10 years

  2. Dawn Shelton says:

    Thank you to the intelligent researchers and scientists. Please continue your hard work and diligent efforts to find a cure for Crohn’s disease. We desperately need a cure! Your commitment is appreciated.

Leave a Comment

Your email address will not be published. Required fields are marked *